Shiba Inu's Pursuit of an ETF Faces Regulatory Challenges
- Experts identify three key conditions for Shiba Inu's U.S. ETF approval, including regulatory compliance and market readiness. - Delays persist as regulators scrutinize Shiba Inu's governance and Coinbase's SHIB futures impact on ETF viability. - A European ETP launch highlights Shiba Inu's global expansion, yet sparks debates over crypto asset classification and market risks.

Source: [1] Analyst Discloses 3 Prerequisites for
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto Mom’s NFT ‘Dog’s Breakfast’ Skewers Regulatory Confusion
- SEC commissioner Hester Peirce announced a satirical NFT collection, "The Dog’s Breakfast," mocking crypto regulatory chaos and self-deprecating her apiculture struggles. - The project features caricatures of crypto stakeholders and regulators, highlighting Peirce’s call for balanced innovation and investor protection frameworks. - Since 2025, the SEC has shifted from aggressive enforcement to clearer guidelines, with Peirce leading a task force to redefine digital asset regulations. - Peirce urged indus

BlockDAG's $376M Presale: Leading Blockchain Innovation or Warning Sign?
- BlockDAG's $376M presale achieved 2,660% ROI, selling 25B tokens across 29 batches with $0.0276 per coin pricing. - CEO Antony Turner, ex-SwissOne Capital, leveraged fintech expertise to drive scarcity-based fundraising and community engagement. - Hybrid DAG-PoW architecture and 2.5M X1 Miner users demonstrate technical progress, but $600M target and post-launch stability remain challenges. - Market analysts caution presale success doesn't guarantee long-term utility, emphasizing need for institutional p

U.S. Imposes 100% Tariffs on Pharmaceuticals to Encourage Local Manufacturing, Raising International Trade Worries
- U.S. government imposes 100% tariffs on imported branded/ patented drugs from Oct 1, 2025, unless manufacturers have U.S. production facilities underway. - Policy aims to boost domestic manufacturing via Section 232 national security investigation, as U.S. pharmaceutical imports hit $213B in 2024. - Analysts warn tariffs risk higher drug prices and supply chain disruptions, with Asian markets reacting sharply to potential losses. - Pharma companies show mixed responses: J&J invests $55B in U.S. operation

Institutions Propel RLUSD's Growth as Stablecoin Connects Conventional and Digital Markets
- Ripple's RLUSD stablecoin gains traction as institutional adoption grows via BlackRock/VanEck funds and exchange listings. - Bybit and other exchanges integrate RLUSD for cross-chain settlements, bridging traditional finance and DeFi ecosystems. - Regulatory clarity and $741M market cap position RLUSD as a specialized stablecoin for cross-border payments and tokenized assets. - SEC litigation delays major exchange listings, but proposed GENIUS Act could accelerate institutional-grade stablecoin adoption.

Trending news
MoreCrypto prices
More








